4/23
07:00 am
prqr
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
Low
Report
ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
4/22
04:31 pm
prqr
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
Low
Report
ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
4/19
07:16 am
prqr
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio [Yahoo! Finance]
Medium
Report
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio [Yahoo! Finance]
4/19
07:00 am
prqr
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
Medium
Report
ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
4/18
12:05 pm
prqr
ProQR Therapeutics (NASDAQ: PRQR) had its price target raised by analysts at Citigroup Inc. from $1.80 to $2.00. They now have a "buy" rating on the stock.
Medium
Report
ProQR Therapeutics (NASDAQ: PRQR) had its price target raised by analysts at Citigroup Inc. from $1.80 to $2.00. They now have a "buy" rating on the stock.
3/19
02:09 am
prqr
ProQR Therapeutics (NASDAQ: PRQR) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
ProQR Therapeutics (NASDAQ: PRQR) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
3/18
03:10 pm
prqr
ProQR Therapeutics (NASDAQ: PRQR) had its price target raised by analysts at Chardan Capital from $2.00 to $2.50. They now have a "buy" rating on the stock.
Low
Report
ProQR Therapeutics (NASDAQ: PRQR) had its price target raised by analysts at Chardan Capital from $2.00 to $2.50. They now have a "buy" rating on the stock.
3/18
03:10 pm
prqr
ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
3/13
07:00 am
prqr
ProQR Announces Year End 2023 Operating and Financial Results
High
Report
ProQR Announces Year End 2023 Operating and Financial Results
3/11
11:00 pm
prqr
ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
3/11
11:00 pm
prqr
ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
2/28
11:06 pm
prqr
ProQR Therapeutics (NASDAQ: PRQR) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
ProQR Therapeutics (NASDAQ: PRQR) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
2/15
07:12 am
prqr
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing [Yahoo! Finance]
Low
Report
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing [Yahoo! Finance]
2/15
07:00 am
prqr
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
Low
Report
ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing
2/12
10:05 pm
prqr
ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Medium
Report
ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.